Taking advantage of the Medtech market potential in India: success will hinge on operating model innovation
Medical technology (Medtech) companies are accelerating their investments in emerging markets, and India is a prime target because of its large population, growing middle class, and improving healthcare infrastructure. To date, most Medtech multinationals have pursued a conservative business strategy and operating model in India, focused on delivering their existing offerings to the premium segments of the market. But the playing field is becoming far more competitive, and companies in search of growth need to move beyond the traditional model.
To gain perspective on this topic, PwC recently surveyed executives from leading global and domestic Medtech companies with India operations representing $1.3 billion in revenues in India, or roughly 40% of the $3 billion Indian market. Their responses, combined with in-depth interviews and PwC’s research and experience in the industry, provide insight on how to succeed in India.
To read the full report visit www.pwc.com/medtechindiastudy
14th Annual CBI Medicaid Drug Rebate Summit
May 16- 18, 2012, Orlando, FL
In its 14th year, the conference provides pharmaceutical, biotech and generic drug manufacturers with the most timely and relevant updates related to the Medicaid Drug Rebate Program.
Amidst monumental healthcare system overhaul, recent CMS proposed AMP rule, major expansion of Managed Medicaid and economic crises at the State level, this conference provides manufacturers with extensive coverage on the latest issues including Medicaid statutory calculations, nuances of the recent CMS proposed AMP rule, managed Medicaid accruals and contracting and CMS reporting. PwC’s Anthony Greco and Ari Ilan will be presenting. For more information visit: http://www.cbinet.com/conference/pc12149%20
May 29-30, 2012, Toronto, ON
BioFinance is the leading investor conference in Canada for the life sciences industry.
This event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector. Presenting companies span a range of industries including: biologics, medical devices, drug delivery, vaccines, diagnostics, bio-energy, green technologies, bio materials, industrial biotech, and research services. PwC is a sponsor of the conference and Nitin Kaushal, from PwC's Pharmaceutical and Life Sciences practice, will be speaking on May 29th. For more information visit: http://www.biofinance.ca/
June 18-21, 2012, Boston, MA
PwC is a sponsor at the world’s largest biotech industry event, BIO 2012. Over 15,000 leaders from more than 65 countries will be attending this global gathering. BIO covers the wide spectrum of life science innovations and application areas, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy. For more information visit: www.bio.org